• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

KLK3 Gene Record

  • Summary
  • Interactions
  • Claims
  • KLK3 354 Druggable Genome

    Alternate Names:

    354
    KALLIKREIN RELATED PEPTIDASE 3
    KLK3
    APS
    KLK2A1
    PSA
    hK3
    176820
    6364
    ENSG00000142515
    OTTHUMG00000182867
    P07288
    PROSTATE SPECIFIC ANTIGEN PRECURSOR (EC 3.4.21.77) (PSA) (GAMMA- SEMINOPROTEIN) (KALLIKREIN 3) (SEMENOGELASE) (SEMININ) (P-30 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P07288]
    KLK3_HUMAN
    PROSTATE-SPECIFIC ANTIGEN
    PKK
    Plasma prekallikrein
    Kininogenin
    Fletcher factor
    Plasma kallikrein light chain
    Plasma kallikrein heavy chain
    Plasma kallikrein
    KLKB1
    Prostate specific antigen
    T36935

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:3.4.21.77
    Human Readable Name DRUGGABLE GENOME
    Human Readable Name PROTEASE
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Short Name Peptidase_S1_S6
    Interpro Type Domain
    Interpro Acc IPR001254
    Interpro Name Peptidase S1/S6, chymotrypsin/Hap
    Gene Biotype PROTEIN_CODING
    (5 More Sources)

    Gene Categories: Category Details

    PROTEASE
    DRUGGABLE GENOME

    Publications:

    Zarghami et al., 1997, Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer., Br. J. Cancer
    Tomera et al., 2001, The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer., J. Urol.
    Kang Z et al., 2004, Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor., Mol Endocrinol
    Yu et al., 1994, Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines., Breast Cancer Res. Treat.
    Munshi et al., 2001, Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide., Cancer
    Vijayakumar et al., 1995, Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer., J Natl Med Assoc
    Verhelst et al., 1994, Octreotide in advanced prostatic cancer relapsing under hormonal treatment., Acta Urol Belg
    Springate et al., 2005, Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models., Cancer Chemother. Pharmacol.
    Weitzman et al., 2000, Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer., J. Urol.
    Bhamre et al., 2003, Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth., Prostate
    Seidman et al., 1992, Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer., J. Urol.
    Fowler et al., 1995, Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment., J. Urol.
    Davis et al., 2000, Inhibition of prostate specific antigen expression by genistein in prostate cancer cells., Int. J. Oncol.
    Sadar, 1999, Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways., J. Biol. Chem.
    Dijkman et al., 1997, Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group., J. Urol.
  • TOPSALYSIN   KLK3

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name PRX302
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • SELENOMETHIONINE   KLK3

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12539231


    Sources:
    NCI

  • ABARELIX   KLK3

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11342922


    Sources:
    NCI

  • BICALUTAMIDE   KLK3

    Interaction Score: 1.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10075669


    Sources:
    NCI

  • APROTININ   KLK3

    Interaction Score: 1.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Plasma kallikrein inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NILUTAMIDE   KLK3

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9186345


    Sources:
    NCI

  • ECALLANTIDE   KLK3

    Interaction Score: 0.86

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Plasma kallikrein inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ANDROSTENEDIONE   KLK3

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8907816


    Sources:
    NCI

  • OCTREOTIDE   KLK3

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7515212


    Sources:
    NCI

  • ESTRAMUSTINE   KLK3

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11391599


    Sources:
    NCI

  • MIFEPRISTONE   KLK3

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9052414 15308689


    Sources:
    NCI

  • FLUTAMIDE   KLK3

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7541862


    Sources:
    NCI

  • VINBLASTINE   KLK3

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1371564


    Sources:
    NCI

  • GENISTEIN   KLK3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10811979


    Sources:
    NCI

  • DOCETAXEL   KLK3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15864591 10687988


    Sources:
    NCI

  • ETOPOSIDE   KLK3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11391599


    Sources:
    NCI

  • TAMOXIFEN   KLK3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7532467


    Sources:
    NCI

  • PROGESTERONE   KLK3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9052414


    Sources:
    NCI

  • Ensembl: ENSG00000142515

    • Version: 101_38

    Alternate Names:
    KLK3 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000142515

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000142515 Ensembl Gene Id
    KLK3 Display Id
    PROSTATE SPECIFIC ANTIGEN PRECURSOR (EC 3.4.21.77) (PSA) (GAMMA- SEMINOPROTEIN) (KALLIKREIN 3) (SEMENOGELASE) (SEMININ) (P-30 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P07288] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P07288

    • Version: January-2014

    Alternate Names:
    KLK3 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.4.21.77

    Publications:

  • HopkinsGroom: P07288

    • Version: 11-September-2012

    Alternate Names:
    KLK3 Uniprot Gene Name
    KLK3_HUMAN Uniprot Id
    354 Entrez Gene Id

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    PROTEASE, DRUGGABLE GENOME

    Publications:

  • NCI: KLK3

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Zarghami et al., 1997, Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer., Br. J. Cancer
    Verhelst et al., 1994, Octreotide in advanced prostatic cancer relapsing under hormonal treatment., Acta Urol Belg
    Davis et al., 2000, Inhibition of prostate specific antigen expression by genistein in prostate cancer cells., Int. J. Oncol.

  • ChemblInteractions: KLK3

    • Version: chembl_23

    Alternate Names:
    KLK3 GENE_SYMBOL
    KLKB1 GENE_SYMBOL
    Plasma kallikrein UNIPROT

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000142515

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000142515 Gene Symbol
    KLK3 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • dGene: KLK3

    • Version: 27-Jun-2013

    Alternate Names:
    354 Gene ID
    APS dGene Synonym
    KLK2A1 dGene Synonym

    Gene Info:

    Gene Categories:
    PROTEASE

    Publications:

  • TTD: Prostate specific antigen

    • Version: 2020.06.01

    Alternate Names:
    KLK3 TTD Gene Abbreviation
    T36935 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21